期刊文献+

重型肝炎外周血T淋巴细胞亚群变化 被引量:2

原文传递
导出
摘要 目的通过测定重型肝炎患者外周血中CD3+、CD3+CD4+及CD3+CD8+T淋巴细胞数量的变化,探讨重型肝炎T淋巴细胞亚群数量的变化与临床转归的相关性。方法使用流式细胞仪对36例重型肝炎早、晚期外周血中CD3+、CD3+CD4+及CD3+CD8+T淋巴细胞数量进行检测。结果 36例重型肝炎早期外周血中CD3+、CD3+CD4+及CD3+CD8+T淋巴细胞数量分别为:(1274.62±273.79)个/μl、(554.27±152.95)个/μl、(541.77±184.77)个/μl,晚期分别为:(874.14±312.89)个/μl、(467.77±144.57)个/μl、(326.86±124.01)个/μl(P分别<0.05、<0.01),有统计学意义;死亡患者早期CD3+、CD3+CD4+及CD3+CD8+T淋巴细胞数量分别为:(1329.50±276.58)个/μl、(731.00±212.81)个/μl、(571.75±231.24)个/μl,晚期分别为:(662.75±187.46)个/μl、(376.50±120.09)个/μl、(205.25±186.03)个/μl(P分别<0.05、<0.01),有统计学意义;成活与死亡患者晚期外周血中CD3+、CD3+CD4+及CD3+CD8+T淋巴细胞数量比较,P<0.01,有统计学意义。结论重型肝炎早期外周血中CD3+、CD3+CD4+及CD3+CD8+T淋巴细胞数量明显高于晚期;成活患者晚期外周血中CD3+、CD3+CD4+及CD3+CD8+T淋巴细胞数量明显高于死亡患者;免疫调节剂的使用,可提高重型肝炎抢救的成功率。
出处 《江苏医药》 CAS CSCD 北大核心 2010年第19期2336-2337,共2页 Jiangsu Medical Journal
  • 相关文献

参考文献5

  • 1中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14013
  • 2Cureil TJ,Coukos G,Zou L,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J]. Nat Med, 2004,10 (9) : 942-949.
  • 3Maini MK, Boni C, Lee CK, et al. The role of virus specific CD8^+ cells in liver damage and viral control during persistent hepatitis B virus infection[J]. J Experimental Medicine, 2000, 191(8):1269-1280.
  • 4MacSween RNM, Burt AD, Portmann BC, et al. Pathology of the liver[M]. 4^th ed. London: Churchill Livingstone, 2002 : 313-362.
  • 5Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, et al. Antigen-antibody immune complexes empower dendritic cells to efficiently primespecifie CD8^+ CTL responses in vivo[J]. J Immunol, 2002,168 (5) : 2240-2246.

共引文献14012

同被引文献26

  • 1肖光明,姚细安,连粤湘,吴茂盛,刘远煌,雷春亮.乙型肝炎患者外周血T淋巴细胞亚群的变化[J].实用肝脏病杂志,2005,8(1):22-24. 被引量:34
  • 2辛绍杰,邹正升,李保森,赵军,徐东平,陈黎明,邢汉前,金磊,王福生.慢性乙型重型肝炎患者外周血各亚群淋巴细胞绝对值的特点[J].第二军医大学学报,2006,27(4):413-416. 被引量:17
  • 3李鸿宾,江晓萍,叶珺,黄浏培.测定慢性乙型肝炎患者外周血T淋巴细胞亚群的临床意义[J].安徽医药,2006,10(8):588-589. 被引量:30
  • 4毛卫林 陈瑜.T细胞亚群对乙型肝炎发病机制的作用.国际流行病学传染病学杂志,2007,34(2):128-130.
  • 5Kaplovitz N. Drug induced liver disorders implication for drug development and regulation[J]. Drug Saf, 2001,24 (3) .-489-490.
  • 6Maini MK,Boni C,Lee CK,et al. The role of virus specif- ic CDS(q-) cells in liver damage and viral control during persistent hepatitis B virus infection [J]. J Exp Med, 2000,191(8) : 1269-1280.
  • 7Ando K, Moriyama T, Guidotti LG, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis [J]. J Exp Med, 1993, 178 (13) : 1541-1554.
  • 8Ghasemi M,Azarnia M,Jamali M,et al.Protective effects of Ephedra pachyclada extract on mouse models of carbon tetrachloride-induced chronic and acute liver failure[J].Tissue Cell,2014,46(1):78-85.
  • 9kker Z,Walubo A,du Plessis JB.The role of the immune system in nevirapine-induced subclinical liver injury of a rat model[J].ISRN Pharm,2012,2012:932542.
  • 10Sharma M,Mohapatra J,Malik U,et al.Selective inhibition of tumor necrosis factor-αconverting enzyme attenuates liver toxicity in a murine model of concanavalin A induced auto-immune hepatitis[J].Int Immunopharmacol,2013,17(2):229-36.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部